Bicycle Therapeutics PLC (BCYC) stock forecast and price target
Price $3.37 · data as of November 13, 2026
12-month price target
Average target$9.17
Upside / downside+172.0%
Analysts6
ConsensusBuy
Low $5.00Average $9.17High $14.00
Gold marker: average target · white marker: today’s price ($3.37)
Analyst ratings
Strong buy 2Buy 4Hold 3Sell 0Strong sell 0
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends December 31, 2026 | $-2.26 | +28.4% | $38M |
| Next fiscal year ends December 31, 2027 | $-2.40 | −6.3% | $5M |
| Next quarter ends December 31, 2026 | $-0.52 | −78.9% | $3M |
| Quarter after ends March 31, 2027 | $-0.61 | +30.3% | $1M |
Consensus of the analysts covering Bicycle Therapeutics, updated daily. In the last 30 days 1 estimates were raised and 0 lowered.
Frequently asked questions
What is the Bicycle Therapeutics stock price target?
The average 12-month target from 6 analysts is $9.17, 172.0% above the current price of $3.37 Targets range from $5.00 to $14.00.
Is Bicycle Therapeutics a buy according to analysts?
The consensus rating is “Buy” (2 strong buy, 4 buy, 3 hold). Ratings are opinions, not guarantees; this is not investment advice.
How much is Bicycle Therapeutics expected to earn?
Analysts expect EPS of $-2.26 for the fiscal year ending December 31, 2026 and $-2.40 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.